Reading diagnostic biomarkers

Effective analysis relies on the optimisation of the interface between the sample and the analysing machine.

Working with a range of commercial partners – including Advion, Owlstone Medical and IMSPEX – we have developed technologies that improve this crucial interface.

We rapidly developed new, more rapid ways to analyse breath samples capable of identifying disease and drug biomarkers.

This success led to a request, in 2015, from Owlstone Medical to collaborate on the Breathfree project which led to the development of the ReCIVA breath sampler.

Having demonstrated that our technique can support COPD diagnosis at the point of care, in 2015, we began work with IMSPEX Diagnostics to adapt their Breathspec instrument for use in the H2020 mass casualty project TOXI-triage where it proved it capabilities. It now being successfully deployed worldwide for COVID-19 testing.

In parallel, we identified Advion’s mass spectrometers as suitable for in-situ analysis and developed a bespoke method for direct breath into the device. This collaborative project led to the 2015 launch of Advion’s vAPCI – now sold globally.

All three products are deployed by diverse institutions worldwide – enhancing early disease diagnoses, improving the speed of contaminant and environmental testing, and supporting the development of a range of other innovative healthcare procedures and products.

Our research underpins Advion’s vAPCI Volatile APCI Analysis technology as well as Owlstone Medical’s ReCIVA and IMSPEX’s BreathSpec devices – all of which are already enjoying global sales.